Related Experiment Video
Updated: Jul 31, 2026
08:03
Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain
Published on: February 22, 2019
Myasthenia gravis: passive transfer from man to mouse
Science (New York, N.Y.)
|October 24, 1975
Summary
Researchers identified a circulating factor in myasthenia gravis patient serum that, when transferred to mice, mimicked disease features. This passive transfer study demonstrated a key serum component
Area of Science:
- Neuroimmunology
- Neuromuscular Disorders
- Autoimmune Diseases
Background:
- Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission.
- The role of serum factors in myasthenia gravis pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the potential of serum from myasthenia gravis patients to induce disease-like features in experimental animals.
- To identify circulating factors responsible for myasthenia gravis pathology.
Main Methods:
- Daily injection of immunoglobulin fractions from myasthenia gravis patient serum into mice for up to 14 days.
- Assessment of neuromuscular junction function, including miniature endplate potential amplitudes and acetylcholine receptor numbers.
- Electrophysiological evaluation of nerve stimulation responses and pharmacological reversal.
Main Results:
- Mice receiving serum immunoglobulin fractions exhibited reduced miniature endplate potential amplitudes.
- A decrease in acetylcholine receptor numbers at neuromuscular junctions was observed in treated mice.
- Some mice displayed decremental responses to repetitive nerve stimulation, which were reversed by neostigmine.
Conclusions:
- This study provides the first evidence of a transferable serum factor that reproduces key features of myasthenia gravis in mice.
- The findings support the hypothesis that circulating antibodies or other factors in myasthenia gravis serum play a direct role in disease manifestation.
- Passive transfer of serum components offers a valuable model for studying myasthenia gravis pathophysiology and developing targeted therapies.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...